Quick Dispatch:
Your aana glp-1 guidelines Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your aana glp-1 guidelines Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement ships.
Need Help?
Questions about aana glp-1 guidelines Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for aana glp-1 guidelines Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement in your area.
A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia | Journal of Anesthesia, Analgesia and Critical Care
22.82
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STO
20.44
A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?
29.62
View of GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice
26.48
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
26.19
Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists
21.51
The Role of GLP-1 RAs in the Management of Type 2 Diabetes and Cardiovascular Risk
26.69
